CL en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF en Please read important disclosure Close important disclosure false
PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
  • NAV
    $111.70

    as of February 27, 2026
  • YTD RETURNS
    8.32%

    as of February 27, 2026
  • Total Net Assets
    $1.31B

    as of February 27, 2026
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

About PPH

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Overview

Why PPH

  • Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
  • Industry Leaders: Index methodology favors the largest companies in the industry
  • Global Scope: Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Performance

Fees

Holdings

Portfolio

Sector Weightings (%) as at 31 Jan 2026

  • Sector

    % of Net Assets
  • Health Care

    99.80
  • Other/Cash

    0.20

Country Weightings (%) as at 31 Jan 2026

  • Country

    % of Net Assets
  • United States

    60.80
  • United Kingdom

    11.69
  • Switzerland

    10.46
  • Denmark

    7.28
  • France

    4.07
  • Japan

    2.76
  • Israel

    2.75
  • Other/Cash

    0.20

Distributions

Team

Literature

PPH